UBS Group Lowers Henry Schein (NASDAQ:HSIC) Price Target to $80.00

Henry Schein (NASDAQ:HSIC) had its target price cut by research analysts at UBS Group from $83.00 to $80.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s target price points to a potential upside of 10.93% from the stock’s current price.

Other research analysts have also issued reports about the stock. Barrington Research restated an “outperform” rating and issued a $90.00 target price on shares of Henry Schein in a report on Wednesday. Mizuho started coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price objective on the stock. Wells Fargo & Company started coverage on shares of Henry Schein in a research report on Friday, February 14th. They set an “equal weight” rating and a $80.00 target price on the stock. StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Stock Performance

Shares of HSIC opened at $72.12 on Wednesday. The company has a 50-day moving average of $74.35 and a two-hundred day moving average of $72.42. The stock has a market cap of $8.99 billion, a P/E ratio of 29.68, a PEG ratio of 2.13 and a beta of 0.91. Henry Schein has a 12-month low of $63.67 and a 12-month high of $82.49. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.66 earnings per share. As a group, research analysts predict that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in Henry Schein by 274.6% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $32,000 after acquiring an additional 335 shares during the last quarter. Investment Management Corp VA ADV purchased a new stake in shares of Henry Schein during the 4th quarter worth about $32,000. Venturi Wealth Management LLC increased its position in Henry Schein by 3,347.1% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the company’s stock worth $41,000 after purchasing an additional 569 shares in the last quarter. Quent Capital LLC raised its holdings in Henry Schein by 91.2% in the fourth quarter. Quent Capital LLC now owns 677 shares of the company’s stock valued at $47,000 after buying an additional 323 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after buying an additional 143 shares during the period. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.